Senores Pharmaceuticals Reports Strong Q2 and H1 FY27 Performance
Senores Pharmaceuticals Ltd · Press Release · 29 Oct 2026, 7:35 pm
Senores Pharmaceuticals Reports Strong Q2 and H1 FY27 Performance Senores Pharmaceuticals posted its highest-ever quarterly revenue and EBITDA in Q2FY27, with revenue growing 24.9% YoY to ₹192.3 crore, EBITDA rising 38% YoY to ₹58 crore, and PAT increasing 22% YoY to ₹37 crore. For H1FY27, revenue reached ₹372.5 crore (+30% YoY), while PAT rose 31% YoY to ₹67 crore. Regulated markets drove growth, surging 34.3% YoY in H1FY27 to ₹264.5 crore. Operating cash flow improved to ₹38 crore. Management reaffirmed FY27 guidance of 30–40% revenue growth and 50–60% PAT growth.
Original exchange filing (PDF)
More announcements from Senores Pharmaceuticals Ltd
- We are pleased to announce that the manufacturing facility of our Subsidiary Company., Ratnatris Pharmaceuticals Private Limited has been awarded with the prestigious PIC/S GMP certification .... · 18 Nov 2026
- Senores Pharmaceuticals Limited has informed the exchange regarding transcript of earnings conference call held on October 29, 2026 · 05 Nov 2026
- Senores Pharmaceuticals Limited has informed the exchange regarding audio recording of earnings conference call for quarter ended September 30, 2026 · 30 Oct 2026
- Senores Pharmaceuticals Limited has informed the exchange regarding submission of statement of deviation or variation in utilisation of funds raised through preferential issue of convertible .... · 29 Oct 2026
- Senores Pharmaceuticals Limited has informed the exchange regarding submission of statement of deviation or variation in utilisation of funds of public issue for quarter ended on September 30, 2026 · 29 Oct 2026
- Senores Pharmaceuticals Limited has informed the exchange regarding Monitoring Agency report for the quarter ended September 30, 2026 · 29 Oct 2026
- We enclose herewith the Investor Presentation for Q2 & H1FY27 · 29 Oct 2026
- Senores Pharmaceuticals Limited has informed the exchange regarding Appointment of joint Statutory Auditor of the Company · 29 Oct 2026
